New therapies

The guidelines discuss newly licensed drugs, including the clinical trials information that established dosing; pharmacokinetics; resistance; and safety, efficacy, and tolerability. The NNRTI etravirine (Intelence), the CCR5 antagonist maraviroc (Celsentri / Selzentry), and the integrase inhibitor raltegravir (Isentress) are included. This information is included in the section A to Z of antiretroviral drugs.

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.